MacroGenics Inc at JPMorgan Healthcare Conference Transcript
Good morning. My name is Gabriel Cruz, and I'm a member of the health care investment banking team here at JPMorgan. Thank you all for joining us today. Today, I have the pleasure of presenting Scott Koenig, CEO of MacroGenics.
Thank you very much. So thank you very much for the opportunity to present at JPMorgan. I will be presenting forward-looking statements during the course of this presentation. So please refer to our SEC filings to understand the risks associated with an investment in MacroGenics.
MacroGenics is a leader in the development of antibody therapeutics for the treatment of cancer. We have developed our company through our core platform technology developed in-house. First one is Fc-engineering, where we've incorporated this technology in 2 of our molecules and have demonstrated coordinate activation of the innate and specific immune responses to produce clinical benefit.
Our second core technology is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
